Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib Study of the Combination Use of Recombinant Human GM-CSF Type II Herpes Simplex Virus (OH2) Injection (Vero Cells) and HX008 Injection in the Treatment of Melanoma

Next Previous
Trial Profile

Phase Ib Study of the Combination Use of Recombinant Human GM-CSF Type II Herpes Simplex Virus (OH2) Injection (Vero Cells) and HX008 Injection in the Treatment of Melanoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OH 2 (Primary) ; Pucotenlimab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Binhui Biopharmaceutical

Most Recent Events

  • 24 Jul 2025 Planned End Date changed from 30 Nov 2023 to 30 Nov 2025.
  • 24 Jul 2025 Planned primary completion date changed from 30 Nov 2023 to 30 Nov 2025.
  • 28 Jan 2023 Planned End Date changed from 30 Nov 2022 to 30 Nov 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top